Previous close | 0.1000 |
Open | 0.1300 |
Bid | 0.0200 |
Ask | 0.1900 |
Strike | 300.00 |
Expiry date | 2022-09-16 |
Day's range | 0.1000 - 0.1300 |
Contract range | N/A |
Volume | |
Open interest | 1.12k |
Vaxxinity missed out on Operation Warp Speed and the first round of COVID-19 vaccines, but CEO Mei Mei Hu is focused on the second generation and ongoing global needs.
Novavax missed Wall Street expectations but remains optimistic about the fourth quarter and 2023.
Novavax (NVAX) reports dismal results in second-quarter 2022. The stock dives in after-market trading after management slashes revenue guidance for 2022 by half.